Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor
Status:
Unknown status
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
One of the greatest problems in renal transplantation is the shortage of donor kidneys.
Kidneys of non-heart-beating donors (NHB) are a possible solution, but transplantation is
accompanied with a high percentage of acute renal failure, caused by ischemia-reperfusion
injury. The increased ischemia-reperfusion injury results in an increased immune activation,
which can lead to more injury of the kidney and additional acute rejections. The hypothesis
of this trial is that ischemia-reperfusion injury can be diminished by ATG. ATG could have
additional favourable effects. To investigate this half of the patients is treated with
additional ATG to the standard immunosuppressive treatment. Calcineurin inhibitors are not
diminished during the first days after transplantation to investigate whether ATG has special
effects on ischemia-reperfusion injury.
Phase:
Phase 3
Details
Lead Sponsor:
Radboud University
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Erasmus Medical Center Leiden University Medical Center Maastricht University UMC Utrecht University Medical Center Groningen